ANTISEL is committed to delivering outstanding customer service 365 days a year.

Our scientific personnel have multifaceted expertise and offers high quality services

ANTISEL through current and future collaborations with commercial, industry and academic partners is focusing on emerging fields in biotechnology and biomarker research.

Our main focus lies on:

Sequencing

Recent rapid advances in next‐generation sequencer (NGS) and computational analyses for handling massive data have enabled us to comprehensively analyze cancer genome profiles at research and clinical levels, such as targeted sequencing for hundreds of genes, whole exome sequencing (WES), RNA sequencing (RNA‐Seq) and whole genome sequencing (WGS).Classic Sanger sequencing, is used to analyze specific genomic regions and to validate NGS data analysis results. ANTISEL provides sequencing and validation services through CEMIA SA

Liquid biopsy

Immunotherapy in oncology requires the discovery, validation and subsequent adoption of robust, sensitive and specific predictive and prognostic biomarkers for daily practice. Until now, anti-PD-L1 immunohistochemistry (IHC) on tissue sections has been the only validated companion diagnostic test for first-line immunotherapy for advanced and metastatic cancer, notably non-small-cell lung cancer (NSCLC). However, the detection of this biomarker presents limitations which have stimulated the development of other biomarkers and other approaches. Within this context, the use of a liquid biopsy (LB) could provide an important complementary or alternative added value to PD-L1 IHC. While LBs have not yet been implemented in routine ImmunoOncology clinical practice, recent promising data and rapidly advancing technologies indicate that this approach has the potential to soon personalize the clinical management of cancer patients receiving ICIs.

Bioinformatics analysis

The analysis of data acquired during NGS experiments needs combined expertise, including Biology, Informatics, Statistics and Mathematics. NGS techniques allow the gathering of a wide range of information about an individual, but these data need to be accurately filtered and interpreted. Bioinformatics data analysis is needed to process this raw information, in order to provide clinicians with a narrow set of relevant data to better understand the starting biological question, and possibly answer it efficiently.

Data management / Clinical Decision Support

Designing and performing biological experiments can be daunting, and if not conceived correctly, can provide suboptimal results. Accurate knowledge of the starting biological question and of specific techniques to face it is fundamental. Our experts are available to help you plan and perform successfully many kinds of scientific projects.

Immunomonitoring during immunotherapies based on multicolor flow cytometry

The acceptance of multicolor flow cytometry (MFC) in clinical laboratory medicine is a major steppingstone towards development of new cell analyses, improvement of accuracy, and finally a new range of diagnostic tests. Applications range from differential blood count determination to the identification of fluorescence-labeled subpopulations of disease-specific cell types in cell suspensions. Even new disease patterns can be identified by MFC. However, MFC is not only applicable for making a diagnosis but also for disease monitoring and routine check-ups. It is often used in oncology-related analyses, such as for leukemia and lymphoma patients as well as for patients with solid tumors by enumerating and characterizing circulating tumor cells. Here, not only cell numbers are relevant but also the degree of antigen expression which can be determined in a standardized way. Next to MFC also image cytometry has entered clinical applications although manual review by pathologists is still standard. Therefore, MFC has become an indispensable technique in the diagnosis, prognosis, and therapeutic response-monitoring of most diseases also including hematological and solid tumors.

We can deliver such analyses regarding immune monitoring during therapies and mode-of-action analyses using our multicolor flow cytometry assays. We review every study after carefully inspecting our customer’s needs. We enjoy equally setting up in vitro model systems using our in-house library of healthy donor material or investigating pre-clinical or clinical samples.

ANTISEL’s immune monitoring services

ANTISEL Services offer quality assured flow cytometry-based immune assessment of peripheral blood and peripheral blood mononuclear cell (PBMCs) samples. We are having great expertise in MFC-based based monitoring of cellular immunity to cancer immunotherapeutic modalities

We provide the following immune monitoring services based on MFC:

• Phenotypic characterization and quantification of T naïve cells, as well as memory T lymphocyte subpopulations, including effector memory, central memory. Analysis of regulatory CD4 or CD8 T cells (Tregs). Analysis of frequency and functionality of myeloid-derived suppressor cells (MDSC). Analysis of the frequency of dendritic cell (DCs) subsets. Analysis of the frequency of other immune cell subsets such as Natural Killer cells, Natural killer T cells (NKT cells) and B cells.
• MFC-based analyses of intracellular effector and regulatory cytokine production by activated cells including, but not limited to, IFN-γ, TNF-α, IL-2, IL-10, IL-17 or TGF-β. 

We also offer:

• ELISpot-based detection of T cell responses to antigenic peptides.
• Monitoring of MHC class I-restricted and MHC class II-restricted T cell responses by applying MHC multimer technology and ELISpot technology.

ANTISEL expertise for the precise analyses of the cellular mechanism underlying the mode- of-action of therapeutic modalities

Cancer immunotherapy, a treatment that selectively augments a patient’s anti-tumor immune response, is a breakthrough advancement in personalized medicine. A subset of cancer patients undergoing immunotherapy have displayed robust and long-lasting therapeutic responses. Currently, the spotlight is on the use of blocking antibodies against the T-cell checkpoint molecules, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1), which have been effectively used to combat many cancers types. Despite the overall enthusiasm, immune checkpoint blockade inhibitors suffer from significant limitations such as high cost, serious toxicity in a substantial proportion of patients, and a response rate as low as 10%-40% in some clinical trials. Therefore, there is an urgent need for combining immune-checkpoint inhibitors with other therapeutic modalities in order to achieve clinical benefits. Such combinations can only be done properly if one knows the exact mode-of-action of the drugs in question. This can be obtained by applying detailed cellular analysis assays as part of the pre-clinical and clinical work. Through the analyses of mechanisms underlying the mode of action of such combinatorial therapeutic treatments, we will be able to define biomarkers that could both predict the response of individual patients to these therapies and provide the means for precise monitoring of their therapeutic outcome. In this era of precision medicine, predictive biomarkers are a hot commodity because they can effectively separate responders from non-responders, and spare non-responders from serious therapy-related toxicity.

We are experts in immune cellular network analyses

ANTISEL with its partners has a long-standing experience in a plethora of assays addressing cellular immunity mediated by a variety of effector lymphocytes including T, NK cell subsets and regulated by macrophages, DCs and MDSCs. Thus, we can help our clients to better understand the cellular mode-of-action taking place during combined therapeutic treatments and in this way enable correct decisions through preclinical and clinical development

ANTISEL provides premium Sanger sequencing services for both plasmid and PCR product through CeMIA SA.

Benefits:

• 3-5 working days turnaround from sample receipt
• High quality reads on the ABI3730xl
• Runs for both tubes and plates
• Free universal primers

For more information, you can download the Method description guide for troubleshooting.

ANTISEL, through CeMIA SA, offers HLA typing for HLA–A, –B, -C, -DRB1 and –DQB1 loci by SBT in low-high resolution analysis. Sample types that can be processed for HLA typing include:

• whole blood
• cord blood
• buccal swab
• extracted gDNA
• Other biological samples can be accepted following communication.

For more information and Instructions for Sample submission, please click here.

We provide Next Generation Sequencing applications using Ion Torrent™ platforms. This sequencing technology is simpler, faster, and more cost-effective and scalable than any other next-generation sequencing (NGS) technology available. Ion Torrent™ next-generation sequencing supports many popular NGS applications, including:

• Targeted Sequencing: Single day, single tube, hundreds of genes
• Exome Sequencing: Unravel disease-causing variants in your research
• Transcriptome Sequencing: Flexible, simple, affordable RNA-Seq within reach
• Genome Sequencing: From microbial outbreak research to discovery

For more information please click here.

ANTISEL, through Thermo Fisher Scientific Inc., provides custom DNA oligos that are made to each customer’s specifications, with rigorous quality control and quick turnaround. They can be used in a variety of applications, including:

• PCR
• cloning
• sequencing
• gene detection

For more information please click here.

We are your partner in innovative scientific solutions, whenever you need us.Every request we receive is taken seriously into consideration.

Please fill in the following form: